Immune checkpoint inhibitor (ICI) therapy is the most mature and frequent approach to cancer immunotherapy, in which the killing effect of T cells is upregulated by targeting co-inhibitory molecules including PD-1/PD-L1. The gene discussed is CD274; the disease is cancer.